Table 1.

Clinical characteristics of MTS in 23 patients with XLA-MTS

SymptomsNumber of patientsMedian onset (years)References
Hearing impairment 18 (78%) 3.5 (33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45) 
Speech delay/abnormality 12 (52%) (35, 37, 38, 39, 42) 
Dystonia 5 (22%) (34, 36, 37, 44) 
Psychological developmental disorder 5 (22%) (34, 37, 40, 42, 45) 
Motor developmental delay 3 (13%) (37, 42) 
Visual impairment 3 (13%) 15 (34, 36, 41) 
Intellectual disability 2 (9%) 17.5 (34, 36) 
Dysgraphia 2 (9%) 17.5 (36, 45) 
SymptomsNumber of patientsMedian onset (years)References
Hearing impairment 18 (78%) 3.5 (33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45) 
Speech delay/abnormality 12 (52%) (35, 37, 38, 39, 42) 
Dystonia 5 (22%) (34, 36, 37, 44) 
Psychological developmental disorder 5 (22%) (34, 37, 40, 42, 45) 
Motor developmental delay 3 (13%) (37, 42) 
Visual impairment 3 (13%) 15 (34, 36, 41) 
Intellectual disability 2 (9%) 17.5 (34, 36) 
Dysgraphia 2 (9%) 17.5 (36, 45) 

XLA, X-linked agammaglobulinemia; MTS, Mohr–Tranebjaerg syndrome. Median onset is shown as years.

or Create an Account

Close Modal
Close Modal